| # | Title | Journal | Year | Citations |
|---|
| 1 | EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version) | Ultraschall in Der Medizin | 2017 | 659 |
| 2 | COVID-19: Discovery, diagnostics and drug development | Journal of Hepatology | 2021 | 302 |
| 3 | Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis | Clinical Gastroenterology and Hepatology | 2018 | 191 |
| 4 | Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort | Hepatology | 2019 | 166 |
| 5 | Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis | Gut | 2013 | 159 |
| 6 | EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version) | Ultraschall in Der Medizin | 2017 | 93 |
| 7 | Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection | Clinical Gastroenterology and Hepatology | 2013 | 61 |
| 8 | Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics | Liver International | 2020 | 58 |
| 9 | Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial | The Lancet Gastroenterology and Hepatology | 2019 | 48 |
| 10 | miRNAs as Potential Biomarkers for Viral Hepatitis B and C | Viruses | 2020 | 43 |
| 11 | Ultra‐short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition | Liver International | 2018 | 30 |
| 12 | Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials | Liver International | 2020 | 22 |
| 13 | Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes | Clinical Infectious Diseases | 2018 | 21 |
| 14 | Non‐F HBV/HDV‐3 coinfection is associated with severe liver disease in Western Brazilian Amazon | Journal of Medical Virology | 2019 | 15 |
| 15 | Hepatitis C Virus | Gastroenterology Clinics of North America | 2015 | 13 |
| 16 | Non-invasive tests for liver fibrosis progression and regression | Journal of Hepatology | 2016 | 13 |
| 17 | Hepatitis D virus: Improving virological knowledge to develop new treatments | Antiviral Research | 2023 | 11 |
| 18 | Assessing liver disease in HIV–HCV coinfected patients | Current Opinion in HIV and AIDS | 2015 | 8 |
| 19 | Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study | International Journal of Cardiology | 2018 | 6 |
| 20 | Survey uncovering variations in the management of primary sclerosing cholangitis across Europe | JHEP Reports | 2022 | 6 |
| 21 | Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies | Liver International | 2020 | 5 |
| 22 | Is it really worth adapting liver stiffness cut‐offs according to AST levels? | Liver International | 2015 | 4 |
| 23 | Editorial: HBV cure—the quest for biomarkers to predict off‐treatment sustained response | Alimentary Pharmacology and Therapeutics | 2021 | 3 |
| 24 | We will not rest on our laurels! | Journal of Hepatology | 2016 | 0 |
| 25 | Farewell from the EASL Secretary General | Journal of Hepatology | 2017 | 0 |
| 26 | IDDF2018-ABS-0067 Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study | Journal of Hepatology | 2018 | 0 |
| 27 | IDDF2019-ABS-0211 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies | Journal of Hepatology | 2019 | 0 |
| 28 | Editorial: The next-generation toolkit for exploring biliary diseases | Current Opinion in Gastroenterology | 2023 | 0 |
